GreyBird Ventures

Genetika+ is a medical platform focused on personalizing treatment for depression by utilizing advanced biological, medical, and genetic data. The company has developed an innovative testing tool that predicts the most effective drug therapy for individual patients, thus enabling faster treatment solutions with reduced side effects and lower dosing requirements. By employing a combination of stem-cell technology, genomics, and artificial intelligence, Genetika+ aims to optimize treatment while also aiding pharmaceutical companies in enhancing their product offerings and streamlining clinical trials. This approach not only tailors treatments to specific patient needs but also seeks to advance care for psychiatric and neurological conditions.

Genetika+ is a medical platform focused on personalizing treatment for depression by utilizing advanced biological, medical, and genetic data. The company has developed an innovative testing tool that predicts the most effective drug therapy for individual patients, thus enabling faster treatment solutions with reduced side effects and lower dosing requirements. By employing a combination of stem-cell technology, genomics, and artificial intelligence, Genetika+ aims to optimize treatment while also aiding pharmaceutical companies in enhancing their product offerings and streamlining clinical trials. This approach not only tailors treatments to specific patient needs but also seeks to advance care for psychiatric and neurological conditions.

Platomics is a Vienna-based company focused on regulatory automation and the development of digital in vitro diagnostic medical devices. The company's flagship product, PlatoX, is a secure cloud platform that provides innovative software solutions and facilitates the exchange of information, products, and services within the IVD industry. Platomics specializes in creating compliant, high-performance analysis services for genetic testing, which can be utilized by manufacturers and laboratories to develop their own compliant products. The company's platform supports affected laboratories with digitization, automation, and regulatory compliance, streamlining processes for laboratories, doctors, and reagent manufacturers alike.

Angstrom Bio is a biotechnology company focused on advancing the study, diagnosis, and treatment of diseases through innovative nucleotide chemistry and machine learning. The company has developed a diagnostics technology specifically aimed at providing high-accuracy and frequency testing for COVID-19 and respiratory pathogens. Utilizing nanopore sequencing, Angstrom's platform enables the counting of individual DNA molecules as they pass through nano-scale pores in a specialized membrane. This approach seeks to reduce patient discomfort and minimize organizational disruption, thereby facilitating laboratories in delivering repeated, high-quality testing solutions.

GNA Biosolutions is a molecular technology company located in Martinsried, Germany, specializing in the development of innovative molecular diagnostic devices for detecting and analyzing DNA. The company utilizes its proprietary Pulse Controlled Amplification technology to enhance nucleic acid amplification and detection, featuring rapid heating and cooling rates. This advancement allows laboratories to efficiently diagnose and amplify human pathogens and DNA, simplifying the molecular testing process. GNA Biosolutions aims to make the power of molecular testing accessible to a broader audience, facilitating both laboratory and on-site applications, as well as Point of Care solutions.

Jiangxi Zhongke Jiufeng Wisdom Medical Technology Co., Ltd. was established in May 2015. Under the strong support of the Jiangxi Provincial Party Committee Government, Nanchang Municipal Government and the High-tech Zone Government, the former Siemens Northeast Asia (Greater China + Korea) Medical Mr. Wu Wenhui, the president, led the team of domestic and international first-class science and technology experts, hospital management experts and industry senior professional managers.

Ceres Nanosciences, Inc., established in 2008 and based in Manassas, Virginia, specializes in the research, development, and commercialization of innovative sample preparation products and diagnostic tests. The company's core technology, Nanotrap, captures, enriches, and preserves biomarkers from various biofluid matrices, facilitating early detection of diseases such as cancer, cardiac, and infectious diseases. Ceres' lead product is a direct antigen test for Lyme disease diagnosis, slated for commercial release in 2015. The company's product pipeline includes advanced sample collection technologies and diagnostics, funded through federal grants and industry collaborations.

Atlas5D, Inc. is a technology company dedicated to improving the quality of life for individuals with reduced mobility. Founded in 2011 and based in Cambridge, Massachusetts, the company specializes in developing and manufacturing advanced sensors that assess brain, neuromuscular, and cardiovascular conditions. Its flagship product, Echo5D, is a passive ambient sensor that unobtrusively measures human movement and behavior around the clock, without the need for wearable devices. This innovative approach allows for continuous tracking of patient ambulation and dexterity in a home environment, providing valuable insights to caregivers and healthcare professionals. Atlas5D serves diverse sectors including biotechnology, pharmaceuticals, insurance, government, and healthcare, aiming to empower patients with actionable data to monitor their health and maintain independence. The company's founders possess strong academic and professional backgrounds, notably from MIT and Harvard Medical School, and Atlas5D has been recognized as an alumnus of prestigious programs such as MassChallenge and TechStars.

Hummingbird Diagnostics GmbH is a German company specializing in the development of innovative diagnostics for early disease detection, personalized medicine, and ongoing health monitoring using miRNA biomarkers from blood samples. Established in 1998 and based in Heidelberg, the company provides a range of services including biomarker extraction, microarray analysis, panel development, validation, and bioinformatics. Hummingbird Diagnostics focuses on harnessing blood-borne miRNAs to enhance understanding of the immune system's response to various diseases. Notably, the company has developed diagnostic tests aimed at identifying late-stage non-small cell lung cancer patients who are most likely to benefit from immunotherapy, thereby enabling healthcare providers to offer more tailored treatment options. Hummingbird Diagnostics operates as a subsidiary of febit holding GmbH.